<DOC>
	<DOCNO>NCT01511198</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial determine dose-response relationship body weight five escalate dos NNC 90-1170 ( liraglutide ) subject type 2 diabetes previously treat oral hypoglycemic agent ( OHA ) .</brief_summary>
	<brief_title>Efficacy Safety Metformin Liraglutide Obese Subjects With Type 2 Diabetes Previously Treated With Oral Hypoglycemic Agent</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetic Treated OHA ( oral hypoglycaemic agent monotherapy least 3 month . Prior use metformin allow Body Mass Index ( BMI ) 27.042.0 kg/m^2 ( inclusive ) HbA1c maximum 10 % base analysis central laboratory Cardiac problem Uncontrolled treated/untreated hypertension Proliferative retinopathy know autonomic neuropathy Recurrent severe hypoglycemia judge investigator Known suspect allergy trial product relate product Use drug ( except OHAs ) , investigator opinion could interfere glucose level body weight contraindication metformin use intolerance metformin 1000 mg ( prior trial entry runin period ) . Stable dos , 3 month great , thyroid hormone replacement allow Known suspect abuse alcohol narcotic Current treatment thiazolidinediones chronic daily use insulin ( 7 day ) within three month absence intercurrent illness TSH ( thyroid stimulate hormone ) 0.2 15 U/mL Type 1 specific cause diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>